ReviewCells2022
Current Progress in Vascular Engineering and Its Clinical Applications.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 43 citations in OpenAlex.
- A 3D-printed extravascular stent containing sirtuin-3 engineered human bone marrow mesenchymal stem cells maintains venous graft patency.Stem cell research & therapy · 2026Article
- 4D Printing in Biomedical Implants and Functional Healthcare Devices.Journal of functional biomaterials · 2026Review
- Biofunctionalized Vascular Access Graft Improves Patency and Endothelialization in a Porcine Arteriovenous Model.Journal of functional biomaterials · 2026Article
- Bioreactor Design and Engineering for Cultivated Meat Manufacturing.Advances in biochemical engineering/biotechnology · 2026Review
- Exploring Perivascular Adipose Tissue Responses to Bioresorbable Thermoplastic Polyurethane Vascular Grafts.Biomaterials research · 2026Article
- Comparative evaluation of cell types for endothelialization in cardiovascular tissue engineering.Iranian journal of basic medical sciences · 2026Review
- Current status, trend and progress of stem cells in tracheal tissue engineering research: an overview and perspectives.Stem cell research & therapy · 2025Review
- Synthetic and Tissue-Engineered Vascular Grafts: Current Status, Emerging Technologies, and Clinical Prospects.Reviews in cardiovascular medicine · 2025Review
- Uniting 4D Printing and Melt Electrowriting for the Enhancement of Regenerative Small Diameter Vascular Grafts.Advanced healthcare materials · 2025Article
- Artificial blood vessels-clinical development of TEVG.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Review
- Interpretable machine learning analysis of immunoinflammatory biomarkers for predicting CHD among NAFLD patients.Cardiovascular diabetology · 2025Article
- In-Situ Vascular Regeneration by Host Cells of Acellular Human Saphenous Vein Implanted in Porcine Carotid Artery.International journal of molecular sciences · 2025Article
- Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy.Reviews in cardiovascular medicine · 2024Review
- Review
- Endothelial progenitor cells for fabrication of engineered vascular units and angiogenesis induction.Cell proliferation · 2024Review
- Applications of extraembryonic tissue-derived cells in vascular tissue regeneration.Stem cell research & therapy · 2024Review
- Harnessing the Regenerative Potential of Fetal Mesenchymal Stem Cells and Endothelial Colony-Forming Cells in the Biofabrication of Tissue-Engineered Vascular Grafts (TEVGs).Journal of tissue engineering and regenerative medicine · 2024Article
- Biological Materials for Tissue-Engineered Vascular Grafts: Overview of Recent Advancements.Biomolecules · 2023Review
- Analysis of flow-induced transcriptional response and cell alignment of different sources of endothelial cells used in vascular tissue engineering.Scientific reports · 2023Article
- Small Extracellular Vesicles Derived from Induced Pluripotent Stem Cells in the Treatment of Myocardial Injury.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Coronary heart disease (CHD) is caused by narrowing or blockage of coronary arteries due to atherosclerosis. Coronary artery bypass grafting (CABG) is widely used for the treatment of severe CHD cases. Although autologous vessels are a preferred choice, healthy autologous vessels are not always available; hence there is a demand for tissue engineered vascular grafts (TEVGs) to be used as alternatives. However, producing clinical grade implantable TEVGs that could healthily survive in the host with long-term patency is still a great challenge. There are additional difficulties in producing small diameter (<6 mm) vascular conduits. As a result, there have not been TEVGs that are commercially available. Properties of vascular scaffolds such as tensile strength, thrombogenicity and immunogenicity are key factors that determine the biocompatibility of TEVGs. The source of vascular cells employed to produce TEVGs is a limiting factor for large-scale productions. Advanced technologies including the combined use of natural and biodegradable synthetic materials for scaffolds in conjunction with the use of mesenchyme stem cells or induced pluripotent stem cells (iPSCs) provide promising solutions for vascular tissue engineering. The aim of this review is to provide an update on various aspects in this field and the current status of TEVG clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.